Open label clinical trial with Rituximab (MabThera ®) in Ankylosing Spondylitis - Extension of open label trial: Re-Treatment of patients who have shown response to first course of Rituximab - Ritux-AS-01 Open label clinical trial with Rituximab (MabThera®) in Ankylosing Spondylitis - Extension of open l ...
Open label clinical trial with Rituximab (MabThera ®) in Ankylosing Spondylitis - Extension of open label trial: Re-Treatment of patients who have shown response to first course of Rituximab - Ritux-AS-01 Open label clinical trial with Rituximab (MabThera®) in Ankylosing Spondylitis - Extension of open l ...
Moderate to severe ankylosing spondylitis who have had an inadequate response to or do not tolerate conventional therapy including NSAIDs, DMARDs and TNF alpha inhibitors Moderate to severe ankylosing spondylitis who have had an inadequate response to or do not tolerate ...
Efficacy of Rituximab (Mabthera) in active ankylosing spondylitis: a clinical and magnetic resonance imaging study - Rituximab in AS Efficacy of Rituximab (Mabthera) in active ankylosing spondylitis: a clinical and magnetic resonance ...
Efficacy of Rituximab (Mabthera) in active ankylosing spondylitis: a clinical and magnetic resonance imaging study - Rituximab in AS Efficacy of Rituximab (Mabthera) in active ankylosing spondylitis: a clinical and magnetic resonance ...
Ankylosing spondylitis (AS) is an inflammatory condition primarily affecting the spine. The disease may remain symptomatic and progressive life-long. It is part of the family of spondyloarthropathies which also comprises psoriatic arthritis, reactive arthritis and enteropathic arthritis. Ankylosing spondylitis (AS) is an inflammatory condition primarily affecting the spine. The disease ...